BofA raised the firm’s price target on Amgen (AMGN) to $307 from $304 and keeps an Underperform rating on the shares. The firm, which adjusted estimates in-line with recent launch trends for key assets, notes that its 2026 and 2027 revenue estimates increase by less than 1% and its 2026 and 2027 EPS estimates increase by about 2%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $327 from $325 at Truist
- Closing Bell Movers: Apple higher after stronger than expected guidance
- Amgen raises FY26 adjusted EPS view to $21.70-$23.10 from $21.60-$23.00
- Amgen reports Q1 adjusted EPS $5.15, consensus $4.77
- Amgen sees FY26 CapEx $2.6B; share repurchases not to exceed $3B